An mGlu4‐Positive Allosteric Modulator Alleviates Parkinsonism in Primates
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder that typically presentsbetween the ages of 35 and 50, with a range of clinical manifestations including motor, cognitive and psychiatric impairments
Injection of HD patient-derived homogenates leads to propagation of mHTT in WT mice but does not induce behavioural changes. Injection of HD patient-derived homogenates exacerbates cognitive deficits in BACHD mice and induces localized aggregation. Injection of HD patient-derived homogenates does not change behaviour of Macaques despite long-term presence of aggregates. Injection of HD patient-derived homogenates does not change endogenous HTT in any of the tested conditions.
Anatomo‐Functional Mapping of the Primate Mesencephalic Locomotor Region Using Stereotactic Lesions